Diurnal Share Discussion Threads

[pejaten] 12/10/2020 05:52

Ex date is 8 am on 12 October.

[s34icknote] 11/10/2020 22:49

Oversubscribed so no overhang ?Up 10 percent tomorrow on press !Buyers in market me thinks

[aimmafia] 11/10/2020 22:23

I think we will push up towards 67p by Wednesday Thursday. There will be some form of overhang to clear but if we get strong buying tomorrow it will clear quickly

[nobbygnome] 11/10/2020 20:59

The answer to my question is Appendix V of the document! The record date was the close of business on the 8th October the day before the offer was announced.

[nobbygnome] 11/10/2020 20:15

So are the shares ex offer now? Presumably they must be...

[dandu69] 11/10/2020 19:15

Thanks for that Billy, perhaps see a raft of buys in the morning following this article? All positive stuff though which gets a ten from len.

[sportbilly1976] 11/10/2020 16:21

dandu69 - here is the full article.



Hidden among the early-stage drug developers listed on AIM is a rare gem: one that already has a product on the market.

Diurnal is one of only three such companies to have had a medicine approved in the US. With Diurnal, it is a treatment for children deficient in cortisol, a hormone that helps the body react to stress by increasing the metabolism of glucose and controlling blood pressure.

The Cardiff-based company, founded in 2004 after it was spun out of Sheffield University, specialises in targeting hormone deficiencies.


Last week, it announced plans to raise about £10m, which it will use to complete an early-stage trial of a new drug, Ditest, in America. Ditest is a pill for hypogonadism, a male condition where the body does not produce enough testosterone. Existing treatments are mostly topical (creams), which can cause safety issues. Analysts predict that this drug, if approved, has blockbuster potential, meaning it could achieve sales of $1bn (£770m) a year.

Diurnal said on Friday that it would raise the cash at 60p a share, raking in £8m via a conditional placing and a further £2m through an open offer. The shares, which have more than doubled since July, closed at 63p, giving the company a value of £76.9m.


Diurnal, which arrived on the junior AIM market in 2015 when it reversed into an existing company and raised £30m, wants to become a global player. It plans to avoid developing treatments for diabetes, a field already dominated by pharma giants Sanofi and Novo Nordisk, instead focusing on conditions where the medical need is unmet.

Its first product, Alkindi, was approved in Europe in 2018 and has recently been approved in America, too. Alkindi is a treatment for patients with adrenal insufficiency, which occurs when the adrenal glands do not produce enough cortisol. The most common symptoms are muscle weakness, fatigue and weight loss.

Diurnal has partnered with a US pharma company, Eton, to commercialise Alkindi, which is aimed at under-18s, and is expected to reach peak sales of $100m. Diurnal will receive royalties. It is also working on an adult version, Chronocort — expected to be an even bigger seller.

Analysts at research firm Calvine suggest Diurnal will remain loss-making until 2023. However, if it is successful in finding partners for Chronocort and Ditest, upfront payments should follow. Panmure Gordon, its broker, has put an 84p target on the stock; Calvine thinks its value is closer to 99p. The natural rhythm of this one looks like a winner. Buy.

[hennes ix] 11/10/2020 15:45

a little bit old, but have to work an family ... always the same with all small biotechs, they need money like vampires blood and I'm a littel disappointed about this. The good thing is: no more fear here for fund raising. That's positive for more investors to take shares here. And also positiv is the little discount and strong standing, good news ahead till the end of this year and at the beginning of 2021 ... price targets may be a little less ... I think we should enter the range 76 to 106 pence and promotion through times should help ... GLA

[dandu69] 11/10/2020 15:24

yes, all we needed was some positive coverage post FDA results to get more investment interest and buyers on board. Should help next week.

[yasrub] 11/10/2020 15:05

Good Sunday Times article, simply setting out the success of alkindi sprinkle and further catalysts to rerate the company. Nice feeling DNL is funded and plenty to shoot at - could get exciting

[royalalbert] 11/10/2020 12:23

Should help to remove RG's shares, really do hope he didn't partake in the placing.

[dandu69] 11/10/2020 09:49

is it possible to copy/paste the full article on here?

[vikingwarrier] 11/10/2020 09:41

ALl looks good to me.

[dandu69] 11/10/2020 08:51

great updates thanks guys

[sportbilly1976] 11/10/2020 08:01

Buy comment with Panmure having an 84p target and Calvinr a 99p one

[sportbilly1976] 11/10/2020 08:00

Diurnal rhythm should be a winnerhttps://www.thetimes.co.uk/article/diurnal-rhythm-should-be-a-winner-ldgnpnl38

[s34icknote] 11/10/2020 07:42

A jump on Monday !This has only one way to go !

[dafad] 11/10/2020 07:34

Sunday Times

Hidden among the early-stage drug developers listed on AIM is a rare gem: one that already has a product on the market.

Diurnal is one of only three such companies to have had a medicine approved in the US. With Diurnal, it is a treatment for children deficient in cortisol, a hormone that helps the body react to stress by increasing the metabolism of glucose and controlling blood pressure.

[dandu69] 10/10/2020 21:50

amen to all that

[royalalbert] 10/10/2020 18:08

Agree, however the placing puts a floor under us, also the future looks very bright, FDA approval doesn't happen to many AIM companies.

[aimmafia] 10/10/2020 17:20

DNL will do very well shirt and long term... the share price will not remain in the 60s for very long. If it wasn't for the placing we would of broke 70p already

[eeza] 10/10/2020 16:23

Only your pocket.

[aimmafia] 10/10/2020 16:07

Nokia's don't break

[dandu69] 10/10/2020 15:47

ah i see....well i thought i`d share it with the group, as my old teachers would say! i`ve got no idea when it comes to such things, i`m still using a 15 year old touch pad nokia mobile, still works a treat!! I have no understandings of social media or anything like that. Looking forward to next week and seeing what the share price brings and the postings on this board. All the best fellow holders.